Exploring Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-Associated Protein 9 (CRISPR-Cas9) as a Therapeutic Modality for Cancer: A Scoping Review · Balasubramanian A, Veluswami K, Rao S et al.
References
- Leading Progress Against Cancer: NCI Fiscal Year 2025 Professional Judgment Budget Proposalhttps://www.cancer.gov/research/leading-progress/2025-professional-judgment-budget-proposal-aag.pdf
- Cancer genesWest J Med VogtPK 2732781581993https://pubmed.ncbi.nlm.nih.gov/8460509/8460509PMC1311753
- The difficulties in cancer treatmentEcancermedicalscience ChakrabortyS RahmanT 06201210.3332/ecancer.2012.ed16PMC402484924883085
- Cancer chemotherapyStatPearls [Internet] AmjadMT ChidharlaA KasiA Treasure Island (FL)StatPearls Publishing2024https://pubmed.ncbi.nlm.nih.gov/33232037/33232037
- On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993Ann Oncol GriffinAM ButowPN CoatesAS ChildsAM EllisPM DunnSM TattersallMH 18919571996877717710.1093/oxfordjournals.annonc.a010548
- Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of actionFront Oncol TilsedCM FisherSA NowakAK LakeRA LesterhuisWJ 9603171220223596551910.3389/fonc.2022.960317PMC9372369
- The role of oncoplastic breast surgery in breast cancer treatmentJ Breast Health EmiroğluM Sertİ İnalA 19112015https://pubmed.ncbi.nlm.nih.gov/28331682/2833168210.5152/tjbh.2014.2215PMC5351526
- High burden of postoperative cancer mortality in LMICsLancet FatiregunOA LasebikanN 3493513972021https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00187-2/abstract3351632110.1016/S0140-6736(21)00187-2
- Postoperative recurrence in locally advanced rectal cancer: how does neoadjuvant treatment affect recurrence pattern?World J Surg Oncol OkamuraR ItataniY FujitaY 2472120233758742210.1186/s12957-023-03136-0PMC10428603
- Integrative approaches to cancer immunotherapyTrends Cancer SzetoGL FinleySD 400410520193131165510.1016/j.trecan.2019.05.010PMC7467854
- Gene therapy for cancer treatment: past, present and futureClin Med Res CrossD BurmesterJK 218227420061698810210.3121/cmr.4.3.218PMC1570487
- Cancer immunotherapy for metastasis: past, present and futureBrief Funct Genomics WangX FanS PanH ChenW WangH 1401461820192999223310.1093/bfgp/ely022
- Gene therapy for severe combined immunodeficiencies and beyondJ Exp Med FischerA Hacein-Bey-AbinaS 217202010.1084/jem.20190607PMC704170631826240
- Gene therapy for cancer - a new dimension and challenge for insurersJ Insur Med RegenauerA 58644820193161808410.17849/insm-48-1-1-6.1
- Viral vector platforms within the gene therapy landscapeSignal Transduct Target Ther BulchaJT WangY MaH TaiPW GaoG 53620213355845510.1038/s41392-021-00487-6PMC7868676
- CRISPR/Cas9 therapeutics: a cure for cancer and other genetic diseasesOncotarget KhanFA PandupuspitasariNS Chun-JieH 5254152552720162725003110.18632/oncotarget.9646PMC5239572
- CRISPR-Cas9: a history of its discovery and ethical considerations of its use in genome editingBiochemistry (Mosc) GostimskayaI 7777888720223617165810.1134/S0006297922080090PMC9377665
- Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal originMicrobiology (Reading) BolotinA QuinquisB SorokinA EhrlichSD 2551256115120051607933410.1099/mic.0.28048-0
- CRISPR/Cas9 as a therapeutic tool for triple negative breast cancer: from bench to clinicsFront Mol Biosci TiwariPK KoTH DubeyR 12144891020233746970410.3389/fmolb.2023.1214489PMC10352522
- Small CRISPR RNAs guide antiviral defense in prokaryotesScience BrounsSJ JoreMM LundgrenM 96096432120081870373910.1126/science.1159689PMC5898235
- Short motif sequences determine the targets of the prokaryotic CRISPR defence systemMicrobiology (Reading) MojicaFJ Díez-VillaseñorC García-MartínezJ AlmendrosC 73374015520091924674410.1099/mic.0.023960-0
- Harnessing CRISPR-Cas9 immunity for genetic engineeringCurr Opin Microbiol CharpentierE MarraffiniLA 1141191920142504816510.1016/j.mib.2014.07.001PMC4155128
- CRISPR/Cas9 for human genome engineering and disease researchAnnu Rev Genomics Hum Genet XiongX ChenM LimWA ZhaoD QiLS 1311541720162721677610.1146/annurev-genom-083115-022258PMC10216851
- Applications of CRISPR-Cas enzymes in cancer therapeutics and detectionTrends Cancer HuangCH LeeKC DoudnaJA 499512420182993704810.1016/j.trecan.2018.05.006PMC6299457
- Methodologies for improving HDR efficiencyFront Genet LiuM RehmanS TangX GuK FanQ ChenD MaW 691920183068738110.3389/fgene.2018.00691PMC6338032
- New approaches and procedures for cancer treatment: current perspectivesSAGE Open Med DebelaDT MuzazuSG HeraroKD 20503121211034366920213440887710.1177/20503121211034366PMC8366192
- Molecular biology at the cutting edge: a review on CRISPR/CAS9 gene editing for undergraduatesBiochem Mol Biol Educ Thurtle-SchmidtDM LoTW 1952054620182938125210.1002/bmb.21108PMC5901406
- The Cell: A Molecular Approach, 2nd EditionSunderland (MA): Sinauer Associates CooperGM Sunderland (MA)Sinauer Associates2000https://www.ncbi.nlm.nih.gov/books/NBK9840/
- Development and potential applications of CRISPR-Cas9 genome editing technology in sarcomaCancer Lett LiuT ShenJK LiZ ChoyE HornicekFJ DuanZ 10911837320162680680810.1016/j.canlet.2016.01.030PMC4772675
- CRISPR/Cas9-mediated gene knockout of NANOG and NANOGP8 decreases the malignant potential of prostate cancer cellsOncotarget KawamuraN NimuraK NaganoH YamaguchiS NonomuraN KanedaY 2236122374620152608747610.18632/oncotarget.4293PMC4673169
- The pluripotency factor nanog promotes breast cancer tumorigenesis and metastasisOncogene LuX MazurSJ LinT AppellaE XuY 265526643320142377085310.1038/onc.2013.209PMC3925756
- Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancersOncogene SiuMK WongES KongDS 350035093220132294565410.1038/onc.2012.363
- Long non-coding RNA PXN-AS1 suppresses pancreatic cancer progression by acting as a competing endogenous RNA of miR-3064 to upregulate PIP4K2B expressionJ Exp Clin Cancer Res YanJ JiaY ChenH ChenW ZhouX 3903820193148817110.1186/s13046-019-1379-5PMC6727519
- CRISPR/Cas9 based genome editing for targeted transcriptional control in triple-negative breast cancerComput Struct Biotechnol J Deepak SinghD HanI ChoiEH YadavDK 238423971920213402593110.1016/j.csbj.2021.04.036PMC8120801
- Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modellingNat Commun ZuckermannM HovestadtV Knobbe-ThomsenCB 7391620152606710410.1038/ncomms8391PMC4467376
- Establishment and characterization of CRISPR/Cas9-mediated NF2−/− human mesothelial cell line: molecular insight into fibroblast growth factor receptor 2 in malignant pleural mesotheliomaCancer Sci WahiduzzamanM KarnanS OtaA 18019311020193041750010.1111/cas.13871PMC6317947
- Activating PTEN tumor suppressor expression with the CRISPR/dCas9 systemMol Ther Nucleic Acids MosesC NugentF WaryahCB Garcia-BlojB HarveyAR BlancafortP 2873001420193065419010.1016/j.omtn.2018.12.003PMC6348769
- Massive genomic rearrangement acquired in a single catastrophic event during cancer developmentCell StephensPJ GreenmanCD FuB 274014420112121536710.1016/j.cell.2010.11.055PMC3065307
- Targeted genomic rearrangements using CRISPR/Cas technologyNat Commun ChoiPS MeyersonM 3728520142475908310.1038/ncomms4728PMC4170920
- KIF5B-RET fusions in lung adenocarcinomaNat Med KohnoT IchikawaH TotokiY 3753771820122232762410.1038/nm.2644PMC6430196
- Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technologyCell Rep BlascoRB KaracaE AmbrogioC 12191227920142545612410.1016/j.celrep.2014.10.051
- Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsiesNat Med LipsonD CapellettiM YelenskyR 3823841820122232762210.1038/nm.2673PMC3916180
- Targeted chromosomal duplications and inversions in the human genome using zinc finger nucleasesGenome Res LeeHJ KweonJ KimE KimS KimJS 5395482220122218396710.1101/gr.129635.111PMC3290789
- Punctuated evolution of prostate cancer genomesCell BacaSC PrandiD LawrenceMS 66667715320132362224910.1016/j.cell.2013.03.021PMC3690918
- CRISPR screen in cancer: status quo and future perspectivesAm J Cancer Res HeC HanS ChangY WuM ZhaoY ChenC ChuX 10311050112021http://www.ncbi.nlm.nih.gov/pubmed/3394834433948344PMC8085856
- Identification and characterization of essential genes in the human genomeScience WangT BirsoyK HughesNW 1096110135020152647275810.1126/science.aac7041PMC4662922
- Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domainsNat Biotechnol ShiJ WangE MilazzoJP WangZ KinneyJB VakocCR 6616673320152596140810.1038/nbt.3235PMC4529991
- Genome-scale CRISPR activation screening identifies a role of ELAVL2-CDKN1A axis in paclitaxel resistance in esophageal squamous cell carcinomaAm J Cancer Res ZhaoWS YanWP ChenDB 1183120092019http://www.ncbi.nlm.nih.gov/pubmed/3128595131285951PMC6610048
- Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activityProc Natl Acad Sci U S A SaalLH JohanssonP HolmK 7564756910420071745263010.1073/pnas.0702507104PMC1855070
- Non-genomic loss of PTEN function in cancer: not in my genesTrends Pharmacol Sci LeslieNR FotiM 1311403220112123650010.1016/j.tips.2010.12.005
- CRISPR-based diagnosticsNat Biomed Eng KaminskiMM AbudayyehOO GootenbergJS ZhangF CollinsJJ 643656520213427252510.1038/s41551-021-00760-7
- CRISPR Cas12a-mediated amplification-free digital DNA assay improves the diagnosis and surveillance of Nasopharyngeal carcinomaBiosens Bioelectron JiangC ZhengX LinL 11554623720233752381110.1016/j.bios.2023.115546
- A universal platform for one-pot detection of circulating non-coding RNA combining CRISPR-Cas12a and branched rolling circle amplificationAnal Chim Acta ChenH ZhuangZ ChenY 340896124620233676477810.1016/j.aca.2023.340896
- Improved vectors and genome-wide libraries for CRISPR screeningNat Methods SanjanaNE ShalemO ZhangF 7837841120142507590310.1038/nmeth.3047PMC4486245
- Protein barcodes enable high-dimensional single-cell CRISPR screensCell WroblewskaA DhainautM Ben-ZviB 1141115517520183034390210.1016/j.cell.2018.09.022PMC6319269
- Pooled CRISPR screening with single-cell transcriptome readoutNat Methods DatlingerP RendeiroAF SchmidlC 2973011420172809943010.1038/nmeth.4177PMC5334791
- Genome-wide CRISPR/Cas9 screening for drug resistance in tumorsFront Pharmacol ZhangZ WangH YanQ 12846101420233808410110.3389/fphar.2023.1284610PMC10710899
- Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutationCancer Res MoynahanME CuiTY JasinM 48424850612001http://www.ncbi.nlm.nih.gov/pubmed/1140656111406561
- Break breast cancer addiction by CRISPR/Cas9 genome editingJ Cancer YangH JaegerM WalkerA WeiD LeikerK WeitaoT 219231920182934426710.7150/jca.22554PMC5771328
- CRISPR/Cas9-mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1-mutated breast cancer cellsBioeng Transl Med MintzRL LaoYH ChiCW 05202010.1002/btm2.10152PMC697146531989039
- Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regressionNucleic Acids Res KooT YoonAR ChoHY BaeS YunCO KimJS 789779084520172857545210.1093/nar/gkx490PMC5570104
- Application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancerFront Endocrinol (Lausanne) MengH NanM LiY DingY YinY ZhangM 11484121420233702059710.3389/fendo.2023.1148412PMC10067930
- Aging-like spontaneous epigenetic silencing facilitates Wnt activation, stemness, and Braf(V600E)-induced tumorigenesisCancer Cell TaoY KangB PetkovichDA 3153283520193075382810.1016/j.ccell.2019.01.005PMC6636642
- Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing miceJ Cachexia Sarcopenia Muscle KandarianSC NosackaRL DelittoAE 11091120920183027053110.1002/jcsm.12346PMC6240747
- Double genetic disruption of lactate dehydrogenases A and B is required to ablate the "Warburg effect" restricting tumor growth to oxidative metabolismJ Biol Chem ŽdralevićM BrandA Di IanniL 159471596129320183015824410.1074/jbc.RA118.004180PMC6187639
- CRISPR-Cas9 screen identifies oxidative phosphorylation as essential for cancer cell survival at low extracellular pHCell Rep MichlJ WangY MonterisiS 1104933820223526357810.1016/j.celrep.2022.110493PMC8924371
- CRISPR/Cas9: a powerful strategy to improve CAR-T cell persistenceInt J Mol Sci WeiW ChenZN WangK 123172420233756969310.3390/ijms241512317PMC10418799
- T cell senescence and CAR-T cell exhaustion in hematological malignanciesJ Hematol Oncol KasakovskiD XuL LiY 911120182997323810.1186/s13045-018-0629-xPMC6032767
- Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: a systematic review and meta-analysisBr J Haematol ShargianL RaananiP YeshurunM Gafter-GviliA GurionR 83884619820223576522010.1111/bjh.18335PMC9542944
- CART-cell therapy: recent advances and new evidence in multiple myelomaCancers (Basel) MartinoM CanaleFA AlatiC 26391320213407206810.3390/cancers13112639PMC8197914
- CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patientsSci Rep SuS HuB ShaoJ 20070620162681818810.1038/srep20070PMC4730182
- TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumorsJCI Insight TangN ChengC ZhangX 5202010.1172/jci.insight.133977PMC710114031999649
- Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cellsImmunity AgarwalS AznarMA RechAJ 238824075620233777685010.1016/j.immuni.2023.09.001PMC10591801
- Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemiaCancer Discov TeacheyDT LaceySF ShawPA 664679620162707637110.1158/2159-8290.CD-16-0040PMC5448406
- Base editing: precision chemistry on the genome and transcriptome of living cellsNat Rev Genet ReesHA LiuDR 7707881920183032331210.1038/s41576-018-0059-1PMC6535181
- Programmable editing of a target base in genomic DNA without double-stranded DNA cleavageNature KomorAC KimYB PackerMS ZurisJA LiuDR 42042453320162709636510.1038/nature17946PMC4873371
- TALEN and CRISPR/Cas genome editing systems: tools of discoveryActa Naturae NemudryiAA ValetdinovaKR MedvedevSP 19406(3)2014PMC420755825349712
- Genome-editing technologies: concept, pros, and cons of various genome-editing techniques and bioethical concerns for clinical applicationMol Ther Nucleic Acids KhanSH 3263341620193096527710.1016/j.omtn.2019.02.027PMC6454098
- Recent advances in improving gene-editing specificity through CRISPR-Cas9 nuclease engineeringCells HuangX YangD ZhangJ XuJ ChenYE 21861120223588362910.3390/cells11142186PMC9319960
- Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joiningNat Biotechnol MaruyamaT DouganSK TruttmannMC BilateAM IngramJR PloeghHL 5385423320152579893910.1038/nbt.3190PMC4618510
- Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificityCell RanFA HsuPD LinCY 1380138915420132399284610.1016/j.cell.2013.08.021PMC3856256
- Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapyCancer Gene Ther AhmadiSE SoleymaniM ShahriyaryF AmirzargarMR OfoghiM FattahiMD SafaM 9369543020233685489710.1038/s41417-023-00597-zPMC9971689
- Overview of delivery of CRISPR/Cas systems, its types and role in genome editing and immunotherapyJ RNA Genomics AliA AslamS TabasumS 665672172021http://www.alliedacademies.org/articles/overview-of-delivery-of-crisprcas-systems-its-types-and-role-in-genome-editing-and-immunotherapy-16610.html
- Recent advances in CRISPR/Cas9 delivery strategiesBiomolecules YipBH 8391020203248623410.3390/biom10060839PMC7356196
- Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editingJ Mol Med (Berl) HanHA PangJK SohBS 6156329820203219862510.1007/s00109-020-01893-zPMC7220873
- Rationally engineered Cas9 nucleases with improved specificityScience SlaymakerIM GaoL ZetscheB ScottDA YanWX ZhangF 848835120162662864310.1126/science.aad5227PMC4714946
- Deletion-based escape of CRISPR-Cas9 targeting in Lactobacillus gasseriMicrobiology (Reading) StoutEA Sanozky-DawesR GohYJ CrawleyAB KlaenhammerTR BarrangouR 1098111116420183002436410.1099/mic.0.000689
- Role of nucleotide identity in effective CRISPR target escape mutationsNucleic Acids Res KünneT ZhuY da SilvaF KonstantinidesN McKenzieRE JacksonRN BrounsSJ 10395104044620183010745010.1093/nar/gky687PMC6212716
- The discovery, mechanisms, and evolutionary impact of anti-CRISPRsAnnu Rev Virol BorgesAL DavidsonAR Bondy-DenomyJ 3759420172874973510.1146/annurev-virology-101416-041616PMC6039114
- Naturally occurring off-switches for CRISPR-Cas9Cell PawlukA AmraniN ZhangY 1829183816720162798473010.1016/j.cell.2016.11.017PMC5757841
- CRISPR ethics: moral considerations for applications of a powerful toolJ Mol Biol BrokowskiC AdliM 8810143120192988532910.1016/j.jmb.2018.05.044PMC6286228
- The promise of CRISPR for human germline editing and the perils of "Playing God"CRISPR J LockeLG 2731320203209125410.1089/crispr.2019.0033PMC7047104
- The first Chinese edited babies: a leap of faith in scienceJBRA Assist Reprod RaposoVL 1971992320193143639910.5935/1518-0557.20190042PMC6724388
- The challenge of CRISPR-Cas toward bioethicsFront Microbiol Gonzalez-AvilaLU Vega-LópezJM Pelcastre-RodríguezLI Cabrero-MartínezOA Hernández-CortezC Castro-EscarpulliG 6579811220213412237310.3389/fmicb.2021.657981PMC8195329
CC BY 4.0. "Exploring Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-Associated Protein 9 (CRISPR-Cas9) as a Therapeutic Modality for Cancer: A Scoping Review" by Balasubramanian A, Veluswami K, Rao S et al., Cureus (2024). https://doi.org/10.7759/cureus.64324. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Peer-reviewed and open access; full text from PubMed Central (PMC11316854). Headings and layout adapted for reading; figures and tables are in the original.